Cordis has inked an exclusive distribution deal to sell Medinol‘s coronary stents in the U.S., the company reported, adding a cobalt-chromium bare-metal stent and a drug-eluting stent to its portfolio.
According to the deal, Cordis plans to start selling Medinol’s NIRxcell BMS immediately and will exclusively distribute the company’s EluNir drug-eluting stent if it wins FDA approval.
“The new Medinol agreement, along with the recent launch of the Tryton side branch stent and two Meril PTCA balloon dilatation catheters, reestablishes Cordis in the U.S. market with a significant interventional cardiology portfolio,” Peter Van Haur, Cordis’ VP of North America sales & marketing, said in prepared remarks.
“By adding these new products to our portfolio, we can make the most significant contribution to the healthcare system and deliver the innovative products and solutions that our customers and their patients are seeking.”
Last week, Medinol announced that it won CE Mark clearance for its EluNir drug-eluting stent – a device designed with a low metal footprint and an elastomeric coating.
In one 958-patient clinical study, the coronary stent had a 12-month target lesion failure rate of 5.4% and a 0% rate of late stent thrombosis, proving non-inferior to the Resolute zotarolimus-eluting stent.
